Sagimet Biosciences Takes the Stage at a Key Healthcare Conference
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing innovative therapeutics aimed at addressing metabolic and fibrotic disorders, has announced an exciting opportunity. The company's management team will participate in the 8th Annual Evercore ISI Healthcare Conference, set to take place soon. This event is crucial for showcasing Sagimet's advancements and connecting with industry leaders.
Details of the Conference Participation
This prominent conference will occur on a Tuesday, with Sagimet's fireside chat scheduled for 12:55 PM ET. The event promises insight into the company's therapeutic innovations designed to tackle metabolic and fibrotic pathways. Individuals interested in the discussion can find a webcast of the chat in the Investors & Media section of Sagimet's official website, which will remain accessible for 90 days after the live event.
Innovative Therapeutics Being Developed by Sagimet
Sagimet is making significant strides in its research and development endeavors. The company's focus is primarily on FASN inhibitors that aim to address the challenges posed by overproduction of palmitate, a fatty acid linked to various health conditions. Notably, denifanstat, a once-daily oral medication, achieved promising results in Phase 2b trials for patients with metabolic dysfunction.
Achievements in Clinical Trials
In the Phase 2b FASCINATE-2 clinical trial aimed at treating a condition known as MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease), denifanstat met all primary endpoints. Additionally, exciting developments are underway in China as a license partner is currently running a Phase 3 clinical trial for moderate-to-severe acne, further showcasing the drug's versatility.
Future Developments and Ongoing Research
Looking forward, Sagimet is exploring the combination of denifanstat and another therapeutic agent, resmetirom, in a Phase 1 pharmacokinetic clinical trial. This combination is particularly aimed at providing treatment options for patients suffering from F4-stage MASH, which is vital considering the rising prevalence of this condition.
Emerging Treatments for Acne
In addition to its primary focus, the company is also advancing another oral FASN inhibitor, TVB-3567, which is currently in Phase 1 trials as a first-in-human study targeting acne. This reflects Sagimet's commitment to addressing a variety of conditions linked to metabolic dysregulation.
Staying Connected with Sagimet Biosciences
For those eager to learn more about Sagimet, the company's website serves as a treasure trove of information. Prospective and existing investors can find valuable insights into the company’s ongoing projects and milestones. Staying updated is crucial as Sagimet continues to innovate in the biopharmaceutical field.
Investor and Media Contacts
Sagimet is always open to communication with its investors and the media. For investor-related inquiries, Joyce Allaire from LifeSci Advisors is available through her email. Meanwhile, Michael Fitzhugh is the media contact who can also be reached via email for related questions. These connections help foster transparent communication about the company's progress and future endeavors.
Frequently Asked Questions
What is Sagimet Biosciences focused on?
Sagimet develops innovative therapeutics targeting metabolic and fibrotic disorders, focusing on FASN inhibitors.
When will Sagimet participate in the healthcare conference?
Sagimet is set to participate in the 8th Annual Evercore ISI Healthcare Conference soon, with a fireside chat scheduled around mid-day.
Where can I watch the webcast of the event?
The webcast will be available in the Investors & Media section of Sagimet’s website and will be accessible for 90 days after the live event.
What is denifanstat and its significance?
Denifanstat is an oral medication that has shown efficacy in clinical trials for treating conditions like MASH and is now being explored for other indications.
Who can I contact for investor inquiries regarding Sagimet?
Investors can reach out to Joyce Allaire from LifeSci Advisors for any investor-related questions.
